Congratulations to our client, U.S.-based SPAC Launch One Acquisition Corp, on signing a definitive merger agreement with Minovia Therapeutics , ahead of an anticipated listing on NASDAQ. The transaction reflects a pre-money valuation of approximately $180 million.
Minovia is a biotechnology company developing innovative therapies based on mitochondrial cell transfer, a groundbreaking approach in the treatment of rare diseases and oncology.
Launch One was represented by:
Aaron M. Lampert, Ephraim Friedman and Ronen Hausirer from our International and Hi-Tech Department;
Guy Gershon from our Labor and Corporate Immigration Department;
Yaron Sever, Lidor Almasy, and Yarden Ravivo from our Tax Department.
